FDA 刚刚下令在所有 GLP-1 药物上添加新的警告,针对一种罕见的眼部疾病,这种疾病与突发、永久性视力丧失有关。
该警告适用于 Ozempic、Wegovy、Mounjaro、Zepbound 和其他 GLP-1 药物。
FDA 发现 NAION(一种由视神经血流减少引起的疾病,目前尚无已知治疗方法可逆转视力丧失)的潜在风险可能增加。
有数百万美国人正在服用这些药物,患者在做出治疗决定前,有权了解完整的风险概况。
The FDA just ordered a new warning on ALL GLP-1 drugs over a rare eye condition linked to sudden, permanent vision loss.
The warning applies to Ozempic, Wegovy, Mounjaro, Zepbound, and other GLP-1 medications.
FDA found a potential increased risk of NAION, a condition caused by reduced blood flow to the optic nerve with no known treatment to reverse the vision loss.
With millions of Americans taking these drugs, patients deserve to know the full risk profile before making treatment decisions.
